Parkinson's disease (PD) is the second most prevalent neurological disorder in humans, which is characterized by the progressive loss of dopaminergic neurons and significant decrease in dopamine levels. Subsquently, there is functional impairment of the motor circuit. Majorly, around 90% of PD cases are not linked to any known cause, while the remaining 10% have familial PD caused by mutations in specific genes like α-synuclein (SNCA), parkin RBR E3 ubiquitin protein ligase (PRKN), PTEN induced kinase 1 (PINK1), leucine rich repeat kinase 2 (LRRK2). The missense mutation, Ala53Thr (A53T) in SNCA is considered to be one of the most prominent risk factors for early-onset PD. Yoon et al. conducted a study where they deleted the A53T-SNCA gene using CRISPR/Cas9 which significantly improved conditions related to PD, such as the overproduction of α-synuclein, reactive microgliosis, dopaminergic neurodegeneration, and PD associated motor symptoms.